You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Tolero's investigational agent dubermatinib will be evaluated in AML patients who harbor a TP53 mutation and/or a complex karyotype.
The study suggested that ALL glucocorticoid resistance stemming from alterations that drive down CELSR2 levels might be combated with the BCL2-targeting drug venetoclax.
The company has seen promising activity for the drug in KRAS-mutated metastatic colorectal cancer, and biomarker-defined patient subgroups with castration-resistant prostate cancer and AML.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
The firm, a spin-out of Barts Cancer Institute, is developing a mass spec-based test for identifying AML patients likely to respond to the drug midostaurin.
The drug has shown in clinical trials to improve outcomes in patients with FLT3 internal tandem duplication and tyrosine kinase domain mutations.
The phase III trial saw significant overall survival and remission rates in relapsed or treatment refractory acute myeloid leukemia cases treated with the FLT3 inhibitor gilteritinib.
A juvenile leukemia patient with a rare FLT3 fusion was treated with precision therapy after researchers used a DNA panel and RNA-seq to analyze his disease.
The drug, which has already been approved for marketing in the US and Japan, will now be reviewed by for potential approval in the European Union.